RT Journal Article
T1 Serum Amyloid A1/Toll-Like Receptor-4 Axis, an Important Link between Inflammation and Outcome of TBI Patients
A1 Farré Alins, Víctor
A1 Palomino Antolín, Alejandra
A1 Narros Fernández, Paloma
A1 López Rodríguez, Ana Belén
A1 Decouty Pérez, Céline
A1 Muñoz Montero, Alicia
A1 Zamorano Fernández, Jorge
A1 Mansilla Fernández, Beatriz
A1 Giner García, Javier
A1 García Feijoo, Pablo
A1 Sáez Alegre, Miguel
A1 Palpán Flores, Alexis J.
A1 Roda Frade, José María
A1 Carabias, Cristina S.
A1 Rosa, Juliana M.
A1 Civantos Martín, Belén
A1 Yus Teruel, Santiago
A1 Gandía, Luis
A1 Lagares Gómez-Abascal, Alfonso
A1 Hernández García, Borja J.
A1 Egea, Javier
AB Traumatic brain injury (TBI) is one of the leading causes of mortality and disability worldwide without any validated biomarker or set of biomarkers to help the diagnosis and evaluation of the evolution/prognosis of TBI patients. To achieve this aim, a deeper knowledge of the biochemical and pathophysiological processes triggered after the trauma is essential. Here, we identified the serum amyloid A1 protein-Toll-like receptor 4 (SAA1-TLR4) axis as an important link between inflammation and the outcome of TBI patients. Using serum and mRNA from white blood cells (WBC) of TBI patients, we found a positive correlation between serum SAA1 levels and injury severity, as well as with the 6-month outcome of TBI patients. SAA1 levels also correlate with the presence of TLR4 mRNA in WBC. In vitro, we found that SAA1 contributes to inflammation via TLR4 activation that releases inflammatory cytokines, which in turn increases SAA1 levels, establishing a positive proinflammatory loop. In vivo, post-TBI treatment with the TLR4-antagonist TAK242 reduces SAA1 levels, improves neurobehavioral outcome, and prevents blood–brain barrier disruption. Our data support further evaluation of (i) post-TBI treatment in the presence of TLR4 inhibition for limiting TBI-induced damage and (ii) SAA1-TLR4 as a biomarker of injury progression in TBI patients.
PB MPDI
SN 2227-9059
YR 2021
FD 2021-05-25
LK https://hdl.handle.net/20.500.14352/8643
UL https://hdl.handle.net/20.500.14352/8643
LA spa
NO Farré Alins, V., Palomino ANtolín, A., Narros Fernández, P. et al. «Serum Amyloid A1/Toll-Like Receptor-4 Axis, an Important Link between Inflammation and Outcome of TBI Patients». Biomedicines, vol. 9, n.o 6, mayo de 2021, p. 599. DOI.org (Crossref), https://doi.org/10.3390/biomedicines9060599.
NO Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional
NO Ministerio de Ciencia, Innovación y Universidades (España)
DS Docta Complutense
RD 22 abr 2025